This study evaluated the usefulness of asialoglycoprotein receptor scintigraphy with 99m Tc-galactosyl human serum albumin ( 99m Tc-GSA scintigraphy) as an early predictor for prognosis of acute liver failure. Forty-eight patients with acute liver failure and without a past history of chronic liver disease were enrolled. Patients were divided into survival and non-survival groups by 28-day mortality. 99m Tc-GSA scintigraphy to detect uptake ratio of the heart at 15 minutes to that at three minutes (HH 15 ) and uptake ratio of the liver at 15 minutes to the liver plus the heart at 15 minutes (LHL 15 ), and measurements of serum total bilirubin, hepatocyte growth factor and prothrombin time were performed immediately after the diagnosis of acute liver failure. Areas under the receiver operating characteristic curves were used to compare the prognostic ability of total bilirubin, hepatocyte growth factor, prothrombin time, HH 15 ratio, LHL 15 ratio and the model for end-stage liver disease score. Clinical characteristics of patients in the survival group (n=20) and in the non-survival group (n=28) were not significantly different. HH 15 and LHL 15 uptake ratios in the survival group were 0.670 and 0.875, and they were significantly lower and higher than those in the non-survival group, respectively. All patients with LHL 15 <0.760 died, and the area under the receiver operating characteristic curve for LHL 15 were significantly larger than the areas under the receiver operating characteristic curves of serum variables and model for end-stage liver disease score. In summary, in patients with acute liver failure without chronic liver disease, HH 15 and LHL 15 of 99m Tc-GSA scintigraphy are more useful variables in predicting prognosis than serum variables and model for end-stage liver disease score.
Hepatic dysfunction is a common feature of multiple organ dysfunction syndrome, and hepatic failure is the most lethal factor in multiple organ dysfunction syndrome. Alanine aminotransferase, bilirubin and prothrombin time (PT) are usually used for accurate assessment of liver function 1,2 , but these parameters are affected by treatments such as blood purification or blood transfusion and therefore cannot be used to accurately evaluate liver function reserve 3 . For this reason, a reliable objective assessment of liver function that will not be affected by treatment is highly desirable.
Asialoglycoprotein receptor (ASGPR) scintigraphy is a direct quantitative evaluation of liver function and relies on the fact that 99m Tc-galactosyl human serum albumin ( 99m Tc-GSA) binds to ASGPR expressed on the surfaces of hepatocytes 4 . Since 1999 we have been using ASGPR scintigraphy with 99m Tc-GSA ( 99m Tc-GSA scintigraphy) to evaluate liver function reserve for patients with acute liver failure. In this retrospective cohort study we examined the prognostic ability of 99m Tc-GSA scintigraphy in predicting 28-day survival of patients with acute liver failure.
PATIENTS AND METHODS Patients
Seventy-nine patients with hepatic failure who had been admitted to our intensive care unit con-Anaesthesia and Intensive Care, Vol. 41, No. 4, July 2013 secutively during the period from 1999 to 2006 underwent 99m Tc-GSA scintigraphy. After excluding 31 patients who had chronic liver diseases, 48 patients with acute liver failure were included in this study. Patients were divided into survival and non-survival groups by 28-day mortality from the diagnosis of acute liver failure and admission to the intensive care unit. Profiles of all the patients are shown in Table 1 . Our Institutional Review Board waived the need for patient informed consent for this study and the ethics approval number was 24-5006.
Measurements of biochemical parameters
For each patient, biochemical parameters known to reflect liver function were measured on the same day when 99m Tc-GSA scintigraphy was performed. These parameters included total bilirubin, direct bilirubin, PT and hepatocyte growth factor. The model for end-stage liver disease (MELD) score, known as a reliable predictor of mortality in patients with chronic liver disease [5] [6] [7] [8] , was calculated using parameters including PT international normalized ratio, serum total bilirubin, serum creatinine and presence of dialysis. Tc-GSA scintigraphy Asialoglycoprotein selectively binds to ASGPR, which characteristically exists on the hepatocyte surface. The activity of ASGPR declines with increasing severity of liver dysfunction because the total volume of ASGPR on the hepatocyte surfaces reflects the total functional volume of the liver. After intravenous injection of 3 mg of 99m Tc-GSA (185 MBq, Nihon Mediphysics, Nishinomiya, Japan), which binds to ASGPR, images were obtained using a gamma camera with a large field of view (GCA-90B, Toshiba, Tokyo, Japan) and a high resolution, parallel hole collimator, which was centred over the liver and precordium. Computer acquisition of the gamma-camera data was started just before the bolus injection of 99m Tc-GSA and was ceased 18 minutes later. Radioactivity of the Tc-GSA immediately binds to ASGPR on surfaces of hepatocytes in the normal liver. As the amount of ASGPR decreases with increasing severity of liver dysfunction, the HH 15 ratio gradually increases and the LHL 15 ratio gradually decreases. 99m Tc-GSA scintigraphy was performed immediately after the diagnosis of acute liver failure. When 99m Tc-GSA scintigraphy was performed several times for each patient during treatments, the first measurement of scintigraphy was used for analysis. The differences in HH 15 and LHL 15 ratios between survival and non-survival groups were compared.
Statistical analysis
Categorical data were analysed using the twotailed chi-square test and expressed as a percentage of the group of origin. Continuous variables were analysed using two-tailed Student's t-tests and expressed as means ± standard error of mean, unless stated otherwise. All probability values were two-tailed and probability values <0.05 were considered statistically significant.
RESULTS
The clinical characteristics of patients in the survival and non-survival groups are shown in Table 1 . There were no significant differences in gender, age and causes of acute liver dysfunction between the two groups.
HH 15 and LHL 15 ratios in the 48 patients with acute liver failure are shown in Figures 2 and 3 , respectively. The HH 15 ratio in the survival group was 0.670±0.095, which was significantly lower than that in the non-survival group (0.775±0.092, P <0.0005). In contrast, the LHL 15 ratio in the survival group (0.875±0.067) was significantly higher than that in the non-survival group (0.750±0.019, P <0.0005).
The patients who did not survive were classified by the cause of death into two subgroups. Subgroup 1 included patients who died of other complications, such as respiratory failure, cardiovascular failure or septic shock. PT immediately before death was maintained at 40% or more in subgroup 1 patients. Subgroup 2 included patients who were thought to have died directly from deterioration of acute hepatic failure. In subgroup 2 patients, PT immediately before death was less than 40% and/or was decreased by 10% or more compared to baseline value at the diagnosis of acute liver failure when 99m Tc-GSA scintigraphy was performed. The LHL 15 ratio in subgroup 1 was 0.851±0.063, which was comparable to that in the survival group, but the LHL 15 ratio in subgroup 2 was 0.633±0.106, which was significantly lower than that in subgroup 1 (P <0.0001; Figure 3 ). All patients with an LHL 15 ratio <0.760 died, but no patients with an LHL 15 ratio ≥0.760 died directly from acute hepatic failure.
Receiver operating characteristic curves were used to assess the prognostic ability of different clinical variables, including LHL 15 ratio, HH 15 ratio, serum total bilirubin, serum direct bilirubin, PT and hepatocyte growth factor (Figure 4) . The area under the receiver operating characteristic curve for the LHL 15 ratio was 0.800±0.063 and the area under the receiver operating characteristic curve for the HH 15 ratio was 0.790±0.066 (P <0.001). Receiver operating characteristic curves showed that LHL 15 and HH 15 ratios were able to predict subsequent mortality more accurately than other factors.
There was no correlation between the MELD score and the HH 15 ratio or between the MELD score and the LHL 15 ratio. MELD scores were 23.3±2.1 in the survival group and 25.7±1.8 in the non-survival group. There was no significant difference between MELD scores between the two groups. There was also no difference between the MELD scores in the two subgroups of patients who died. The area under the receiver operating characteristic curve for the MELD score was 0.612±0.086 which was significantly lower than that for the LHL 15 ratio (0.800±0.063, P <0.001; Figure 5 ), suggesting that the LHL 15 ratio was able to predict subsequent mortality more accurately than the MELD score.
DISCUSSION 99m
Tc-GSA scintigraphy is a liver scintigraphy using the synthetic glycoprotein-99m Tc-GSAthat specifically binds to ASGPR expressed on the membrane surfaces of hepatocytes 4 . This scintigraphy reflects liver function directly in a quantitative fashion. 99m Tc-GSA is different from the nuclide of traditional liver scintigraphy which binds to the reticuloendothelial system; instead it binds to the specific receptor expressed on the surface membrane of the hepatocyte 9-12 .
The ASGPR is expressed only on normal hepatocytes and not on liver cancer cells and it decreases according to the number of functional hepatocytes. As such, 99m Tc-GSA scintigraphy is useful in evaluating liver function reserve in patients with chronic liver disease or for hepatic functional assessment before or after liver resection [13] [14] [15] [16] [17] [18] . This scintigraphy remains useful even for patients with jaundice caused by fulminant hepatitis and/or liver failure, because bilirubin does not disturb the binding of 99m Tc-GSA to hepatocytes 19, 20 . Moreover, this scintigraphy also has the advantage of providing a reliable and objective evaluation of hepatocyte function without being confounded by transfusion of blood product or the use of blood purification therapy. Figure 4 : Receiver operating characteristics curves for different clinical variables to predict mortality. The area under the receiver operating characteristics curve for LHL 15 was 0.800 and for HH 15 was 0.790 (P <0.001), which efficiently predict mortality. Area under the receiver operating characteristic curves for T Bil, D Bil, HGF and PT (area under the receiver operating characteristic curves=0.663, 0.647, 0.591 and 0.542, respectively) were significantly lower than those for LHL 15 and HH 15 . LHL 15 =reflects rate of accumulation in the liver, HH 15 =reflects rate of disappearance in blood, T Bil=total bilirubin, D Bil=direct bilirubin, HGF=hepatocyte growth factor, PT=prothrombin time. 15 and MELD score to predict mortality. The area under the receiver operating characteristics curve for LHL 15 (0.800, P <0.001) was higher than that for MELD score (0.612). LHL 15 =reflects rate of accumulation in the liver. MELD score=model for end-stage liver disease score. In this minimally invasive scintigraphy, patients only need to lie down for about 20 minutes following nuclide injection. However, this investigation is relatively expensive; the cost of each scintigraphy inspection is about 38,000 Japanese yen or US$380, and there are expensive capital costs if the institution has no ordinary gamma camera or single photon emission computed tomography system. Another disadvantage is that the critical condition of a patient may prevent the patient from being moved to the inspection room for the scintigraphy.
Although the MELD score is known as a predictor of mortality in patients with chronic liver disease [5] [6] [7] [8] , our study showed that this score could not reliably predict the prognosis of patients with acute liver failure. Moreover, the results showed that the MELD score did not correlate with the 99m Tc-GSA indices, suggesting that HH 15 and LHL 15 ratios are independent predictors of prognosis in patients with acute liver failure.
The HH 15 ratio in patients with chronic hepatitis is comparable to that in healthy subjects, but in patients with acute hepatitis it is slightly increased. In contrast, the LHL 15 ratio becomes progressively lower from chronic hepatitis through acute hepatitis to liver cirrhosis and fulminant hepatitis 21 . In this study, patients in the nonsurvival group with acute liver failure and without a past history of hepatic disease showed a significantly higher HH 15 ratio and lower LHL 15 ratio compared to those of patients in the survival group. Since there was no patient in the survival group whose LHL 15 ratio was <0.760, 99m Tc-GSA scintigraphy appears to be a useful early predictor of survival for patients with acute liver failure. Moreover, the LHL 15 ratio was ≥0.760 in patients in the non-survival subgroup who maintained their usual parameters of liver function until just before death, and the LHL 15 ratio was <0.760 in patients who also had deterioration in other parameters of liver function such as PT. Consequently, this result suggests that the LHL 15 ratio is relatively specific in predicting the cause of subsequent deterioration and death, and not just mortality. Whereas patients with an LHL 15 ratio ≥0.760 may be rescued by intensive care support and prevention and treatment of sepsis, those with an LHL 15 ratio <0.760, despite supportive therapy such as plasma exchange, may need to be listed for urgent liver transplantation.
Although our results showed that 99m Tc-GSA scintigraphy was a promising tool, we must interpret these results with caution. First, this study was a retrospective single-centre study. Although the treatment of acute liver failure was not altered according to the results of the scintigraphy, we cannot exclude the presence of unmeasured bias because the attending clincians, data collectors and analysts were not blinded to the results of the study. The second limitation is that the sample size was small and hence further analysis of the utility of 99m Tc-GSA scintigraphy in patients with different causes of acute liver failure was not possible. Further prospective multi-centre studies are needed to evaluate and confirm the utility of 99m Tc-GSA scintigraphy as an early predictor of subsequent survival and the requirement for liver transplantation in patients with acute liver failure.
CONCLUSION
In patients with acute liver failure without a past history of liver disease, HH 15 and LHL 15 ratios obtained by 99m Tc-GSA scintigraphy at the time of diagnosis of acute liver failure were strong predictors of 28-day mortality, especially when the cause of death was due to progressive liver failure instead of complications of acute liver failure such as sepsis. This scintigraphy may prove to be useful in assisting clinicians in their clinical decisionmaking and in formulating treatment policy, such as an indication for liver transplantation for patients with acute liver failure.
